Raymond James cuts target for Insmed stock from USD 187.00 to USD 173.00

Published on 10/27/2026 at 22:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Raymond James cut its target from USD 187.00 to USD 173.00 on October 20, 2026. Insmed stock costs EUR 84.87 on October 27, 2026 at Lang & Schwarz.

Analyst target and reporting date

Raymond James lowered its Insmed target from USD 187.00 to USD 173.00 on October 20, 2026.
Insmed will publish third-quarter 2026 results on October 29, 2026.
Insmed stock costs EUR 84.87 at Lang & Schwarz on October 27, 2026 at 10:47 p.m. CEST.

INSM, US4576693075, Illustration mit AI erstellt.

Insmed stock (ISIN US4576693075) is at EUR 84.87 at Lang & Schwarz on October 27, 2026 at 10:47 p.m. CEST. Markets Insider reported on October 20, 2026 that Raymond James lowered its Insmed target from USD 187.00 to USD 173.00 while keeping an Outperform rating.

Target cut meets a heavy results test

The lower target comes shortly before Insmed's third-quarter update. Insmed lists October 29, 2026 as the date for its third-quarter 2026 financial results.

The previous quarterly report gives investors a demanding comparison. In the second quarter of 2026, revenue reached USD 425.49 million, up 296.10 percent from the same quarter of 2025, while adjusted earnings per share were negative USD 0.06 versus a negative USD 0.67 consensus estimate, according to MarketBeat on October 20, 2026.

What does the next report need to show?

The next report will be measured against USD 395.50 million of second-quarter revenue consensus and the prior-year adjusted earnings per share figure of negative USD 1.70. The same MarketBeat report said Insmed's average 12-month analyst target was USD 200.30 from 25 analysts, including 22 buy ratings.

Three dated developments

On October 19, 2026, Insmed launched BRINSUPRI tablets in Japan, according to the company investor page. On October 20, 2026, Insmed appointed Paul Hudson and Utpal Koppikar as independent directors. On October 21, 2026, Morgan Stanley maintained its Overweight rating while cutting its target from USD 218.00 to USD 213.00, according to GuruFocus.

Stock position before October 29

MarketBeat listed a 12-month range of USD 90.39 to USD 212.75 and a market capitalization of USD 20.81 billion on October 20, 2026. The wide valuation spread leaves the October 29 report as the next dated test for revenue growth, product execution and analyst expectations.

Insmed was trading at EUR 84.87 at Lang & Schwarz on October 27, 2026 at 10:47 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Insmed stock.